For example, PCK1 inhibitors should be used in tumors of non-gluconeogenic organs (colorectal cancer, lung cancer, melanoma, breast cancer, pancreatic cancer, stomach cancer) to exert anticancer effects, while PCK1 expression should be promoted in tumors of gluconeogenic organs (HCC and RCC) to inhibit tumor progression. Here, PCK1 is linked to lung carcinoma.